文献速递肝病

黑人患者接受来迪派韦联合索磷布韦治疗丙型肝炎8周与12周疗效无差异

No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-11

本研究为观察性研究,纳入Kaiser Permanente北加州分会中符合8周来迪派韦联合索磷布韦治疗条件的基因1型丙型肝炎病毒感染患者,比较8周与12周治疗的持续病毒学应答12周(SVR12)。在435例符合8周方案的黑人患者中,8周与12周治疗的SVR12分别为95.6%与95.8%(P=0.90),无统计学显著差异,与指南推荐12周不同。

要点

  • 黑人患者8周与12周来迪派韦联合索磷布韦的SVR12分别为95.6%与95.8%,无显著差异。
  • 男性、瞬时弹性成像或FIB-4评分较高、INR和胆红素较高、白蛋白较低、肥胖、糖尿病及每周饮酒≥15杯与接受12周治疗独立相关。
  • 上述因素与8周治疗后SVR12降低无关。

核心结论

  • 在黑人患者中,8周与12周来迪派韦联合索磷布韦方案的SVR12无统计学显著差异,与指南推荐12周不同。
  • 符合8周治疗条件的患者中,部分临床特征与接受12周治疗相关,但与8周治疗后SVR12降低无关。
  • 作者认为较短疗程可能可以在不损害疗效的情况下更广泛使用。

研究设计与样本

  • 观察性研究,纳入Kaiser Permanente北加州分会2014年10月至2016年12月期间接受8周或12周来迪派韦联合索磷布韦治疗的基因1型丙型肝炎病毒感染成员。
  • 共2653例符合8周治疗条件,其中1958例(73.8%)接受8周治疗,695例(26.2%)接受12周治疗;黑人患者435例。
  • 使用χ2分析比较8周与12周治疗的SVR12,并使用调整的Poisson模型识别与接受12周治疗相关的因素。

主要发现

  • 在2653例符合8周治疗条件的患者中,8周与12周治疗组的SVR12均为96.3%(P=0.94)。
  • 在435例符合8周治疗条件的黑人患者中,8周与12周治疗的SVR12分别为95.6%与95.8%(P=0.90),无统计学显著差异。
  • 男性、较高的瞬时弹性成像或FIB-4评分、较高的INR和胆红素水平、较低的白蛋白水平、肥胖、糖尿病及每周饮酒≥15杯与符合8周条件患者接受12周治疗独立相关,但与8周治疗后SVR12降低无关。

临床怎么用

  • 作者认为,较短疗程可能可以在不损害疗效的情况下更广泛使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week treatment course for black patients, but studies have not compared the effectiveness of 8 vs 12 weeks in black patients who are otherwise eligible for an 8-week treatment regimen. METHODS: We conducted an observational study of Kaiser Permanente Northern California members with HCV genotype 1 infection who were eligible for 8 weeks of treatment with ledipasvir and sofosbuvir (treatment-naïve, no cirrhosis, no HIV infection, level of HCV RNA <6 million IU/mL) and were treated for 8 or 12 weeks from October 2014 through December 2016. We used χ2 analyses to compare sustained virologic response 12 weeks after the end of treatment (SVR12) among patients treated for 8 vs 12 weeks, and adjusted Poisson models to identify factors associated with receipt of 12 weeks of therapy among patients eligible for 8 weeks. RESULTS: Of 2653 patients eligible for 8 weeks of treatment with ledipasvir and sofosbuvir, 1958 (73.8%) received 8 weeks of treatment and 695 (26.2%) received 12 weeks; the proportions of patients with SVR12 were 96.3% and 96.3%, respectively (P = .94). Among 435 black patients eligible for the 8-week treatment regimen, there was no difference in the proportions who achieved an SVR12 following 8 vs 12 weeks' treatment (95.6% vs 95.8%; P = .90). Male sex, higher transient elastography or FIB-4 scores, higher INR and level of bilirubin, lower level of albumin, obesity, diabetes, and ≥15 alcohol drinks consumed/week were independently associated with receiving 12 weeks of treatment among patients eligible for the 8-week treatment regimen, but were not associated with reduced SVR12 after 8 weeks of treatment. CONCLUSION: In an observational study of patients who received ledipasvir and sofosbuvir treatment for HCV genotype 1 infection, we found that contrary to guidelines, 8-week and 12-week treatment regimens do not result in statistically significant differences in SVR12 in black patients. Patient characteristics were associated with receipt of 12-week regimens among patients eligible for 8 weeks, but were not associated with reduced SVR12 after 8 weeks. Shorter treatment courses might therefore be more widely used without compromising treatment effectiveness.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Marcus JL, Hurley LB, Chamberland S, et al. No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. Clin Gastroenterol Hepatol. 2018. PMID: 29535057. doi:10.1016/j.cgh.2018.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。